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Abstract. Macrophages demonstrate plasticity, and tumor-
associated macrophages (TAM) can function as immuno- 
suppressive cells in the tumor microenvironment. Therefore, 
in this study, we aimed to reprogram TAM in vitro with 
cytokine signal alteration. Granulocyte macrophage colony 
stimulating factor (GM-CSF) treatment alone did not lead to 
changes in the expression of M1 (including IL-1β, TNFα and 
CXCL-10) or M2 (including CD36, CD206 and CCL17) mole-
cules by TAM in vitro, although they adopted a round 
morphology and were less adhesive to the culture dish. When 
macrophage colony stimulating factor (M-CSF) signals were 
suppressed by siRNA against the M-CSF receptor (M-CSFR) 
in conjunction with GM-CSF treatment, the signal transduction 
pathway of TAM was altered, and the expression of STAT1, 
STAT5 and STAT6, which are usually expressed by dendritic 
cells, was increased. However, the same treatment did not 
alter the TAM expression pattern of M1/M2 marker molecules. 
With respect to the NF-κB pathway, GM-CSF and M-CSFR 
siRNA combination treatment significantly induced the 
expression of p65, which is usually not expressed by TAM, 
while p50 and p105 expression by TAM was not affected by 
the treatment. These findings indicate that our model could 
not redirect TAM to a monocyte-derived dendritic cell-like 
phenotype based on the analysis of M1/M2 marker expression, 
but it was able to modify cell signaling pathways toward a 
dendritic cell-like pattern. Therefore, the present data suggest 
that TAM demonstrate plasticity toward dendritic cell-like 
signal transduction patterns, and that the alteration of the 
tumor microenvironment has the potential to reverse the 
immunosuppressive properties of TAM.
Introduction
Tumor-infiltrating myeloid cells are immature cells that are 
activated and matured under the influence of the tumor micro-
environment and composed of two main subtypes, granulocytes 
and monocytes/macrophages (1,2), which have immuno-
suppressive properties (3). Among these cells, CD11b+Gr-1+ 
granulocyte-lineage cells, also referred to as myeloid-derived 
suppressor cells (4,5), are present in bone marrow, spleen, and 
tumor tissue of the tumor-bearing host and suppress T-cell 
functions (6-9). In contrast, tumor-infiltrating monocyte/macro-
phage-lineage cells, referred to as tumor-associated macrophages 
(TAM), show immunosuppressive properties (10).
The number of infiltrating TAM, which is evaluated as the 
number of CD68+ cells, seems to be inversely correlated with 
patient prognosis. With the exception of colon cancer and 
melanoma, the majority of tumors, including breast, kidney, 
prostate, and uterine corpus, show an increased number of 
TAM associated with poorer patient prognosis (11). In addition, 
Takeya's group clearly demonstrated that the number of 
tumor-infiltrating CD163 and CD204 positive cells, which are 
other useful markers of TAM, showed an inverse correlation 
with the prognosis of glioma patients (12). The relationship 
between TAM infiltration and poor prognosis may in part result 
from the secretion of epidermal growth factor (EGF) by 
TAM, which are distributed mainly at the infiltration border 
of the tumor tissue and perivascular areas at the tumor site. 
The tumor cells express EGF receptor (EGFR) and are attracted 
by TAM-secreted EGF, resulting in tumor infiltration into 
mesenchymal tissue or contact with blood vessels (13-16). 
Moreover, the fact that TAM infiltration and patient prognosis 
are not always inversely correlated indicated that various 
tumors activate TAM differently (11). Our group previously 
reported that the expression of cytokines, chemokines, and 
their receptors was tumor-type dependent, but that the site of 
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inoculation (skin, liver, or brain in our model) did not affect 
TAM characteristics (17). Our reports suggest that macrophages 
can be differentially activated and matured depending on 
tumor-derived factors.
Plasticity is an important characteristic of macrophages. 
Indeed, macrophages can be redifferentiated when the micro-
environment of cells is changed (18,19). Both monocyte/
macrophages and monocyte-derived dendritic cells (MoDC) 
originate from a common progenitor, Ly6Chigh monocyte 
progenitor cells, and macrophages have the potential to be 
re-directed toward a MoDC-like phenotype (20). Therefore, in 
this study, we aimed to redirect TAM toward a dendritic-cell-
like phenotype utilizing cytokine and siRNA treatment.
Materials and methods
Mice. Male 6- to 8-week-old C57BL/6 and BALB/c mice were 
purchased from SLC (Wilmington, MA, USA). OT-II.2a micro-
injected/Rag1 knockout mice (OT-2 mice) were purchased 
from Taconic (Germantown, New York, USA).
Cell line. A murine colon carcinoma cell line (MCA38) was 
cultured in RPMI-1640 medium containing 10% fetal calf 
serum, L-glutamine, and penicillin-streptomycin (all from 
Invitrogen Life Technologies, Tokyo, Japan). Cells were main-
tained at 37˚C in a humidified 5% CO2 atmosphere.
Implantation of tumor cells. Mice were inoculated with 3x106 
cells injected subcutaneously into the abdominal wall space.
Isolation of tumor-infiltrating cells. Mice were euthanized 14 
or 21 days after tumor implantation, and the tumor-infiltrating 
cells were prepared. The tumors were collected and minced 
into small pieces before incubation for 15 min at 37˚C with 
the following enzymes dissolved in HBSS: collagenase type I 
(0.05 mg/ml), collagenase type IV (0.05 mg/ml), hyaluronidase 
(0.025 mg/ml, all from Sigma Chemical Co., St. Louis, MO, 
USA), DNase I (0.01 mg/ml), and soybean trypsin inhibitor 
(0.2 trypsin inhibitor unit/ml, both from Roche Diagnostics, 
Nutley, NJ, USA). Digested cells were harvested, and the red 
blood cells were lysed with hypotonic buffer (0.155 M NH4Cl, 
0.1 mM EDTA, 10 mM kHCO3) for 1 min. F4/80+ cells were 
isolated using biotin-conjugated anti-F4/80 antibody (clone 
BM8, Invitrogen, Carlsbad, CA), followed by treatment with 
anti-biotin magnetic immunobeads according to the manu-
facturer's instructions (MACS, Miltenyi Biotec, Berdish- 
Gladbach, Germany).
Multiple PCR analysis. Total RNA was purified using TRIzol 
(Invitrogen Life Technologies), and 600 ng total RNA was 
used for reverse transcription with Superscript III reverse 
transcriptase (Invitrogen Life Technologies). For multiplex 
PCR analysis, 100 ng cDNA samples or positive control DNA 
mixtures were mixed with a multiple primer pair mixture, 
buffer, and Taq polymerase, which were provided by the 
Multiplex PCR kits for mouse Chemokine Receptors (Sets 1 
and 2), Chemokine Genes (Sets 1 and 2), Signaling Receptor 
(Set 1), Sepsis Cytokines (Set 2), Inflammatory Cytokine Genes 
(Set 1), CD Antigen (Set 1), and TH1/TH2 Cytokines (Set 2, 
all from Maxim Biotech, Inc, South San Francisco, CA, USA), 
and then subjected to PCR using the conditions indicated in 
the manufacturer's instruction manual. The amplified DNAs 
were analyzed by 5% acrylamide gel electrophoresis followed 
by ethidium bromide staining.
Real-time PCR analysis. Total RNA was purified using TRIzol 
(Invitrogen Life Technologies), and 600 ng total RNA was used 
for reverse transcription with Superscript III reverse trans-
criptase. For real-time PCR analysis, 5 µl cDNA samples 
diluted 20X, 1 µl each of the upper and lower primer, 3 µl 
PCR-grade water (Roche Diagnostics, Indianapolis, IN, USA), 
and 10 µl 2X concentrated SYBR Green and Taq enzyme-
premixed reaction mixture (SYBR® Premix Ex Taq™, Takara 
Bio, Japan) were used. Some of the primer pair sequences 
used in this analysis are indicated in our previous papers 
(21,22). The sequences of the primer pairs used only in this 
repor t  and not previously a re:  IFNγ,  5'-CGGGAC 
AGTCATTGAAAGCCTA-3', 5'-GTTGCTGATGGCCTG 
ATTGTC-3'; CCR2, 5'-GCAAGTTCAGCTGCCTGCAA-3', 
5'-ATGCCGTGGATGAACTGAGGTAA-3'; CX3CR1, 
5'-TGACCCTGCAAGCATCACGTA-3', 5'-CAATGTAA 
GCCTGCAAATGAGACC-3'; IL-4, 5'-TCTCGAATGTAC 
CAGGAGCCATATC-3', 5'-AGCACCTTGGAAGCCCTAC 
AGA-3'; IL-6, 5'-CCACTTCACAAGTCGGAGGCTTA-3', 
5'-GCAAGTGCATCATCGTTGTTCATAC-3'. The reaction 
conditions consisted of one 5-min cycle at 95˚C, followed by 
45 cycles at 95˚C for 10 sec, and 72˚C for 10 sec. The reaction 
and analysis were performed with a Light Cycler instrument 
(Roche Diagnostics, Indianapolis, IN, USA).
SDS-PAGE and immunoblotting. F4/80+ cells isolated from 
tumor tissues were washed three times with PBS before being 
incubated on ice for 1 h with lysis solution [50 mM Tris-HCl, 
pH. 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM 
EGTA, 1 mM PMSF, 5 mM iodoacetamide, 1 mM Na3VO4, 
and protease inhibitor cocktail (Sigma Chemical Co., P-8340)]. 
The supernatants were collected and subjected to electro-
phoresis on 10% PAGE gels. After transferring the proteins 
onto polyvinylidene difluoride membranes (Bio-Rad Labora-
tories, Hercules, CA, USA), the membranes were blocked 
with skim milk and then reacted for 1 h with 2 µg/ml of the 
following antibodies diluted in a primary antibody signal-
enhancing solution (Can Get Signal™, Immunoreaction 
Enhancer Solution 1, Toyobo Co, Ltd., Osaka, Japan): anti-
mouse stat1 (C-terminus, clone 42), anti-mouse phospho-specific 
stat1 (pY701, clone 14), anti-mouse stat3 (clone 84), anti-mouse 
phospho-specific stat3 (pY705, clone 4), anti-mouse stat4 
(clone 8), anti-mouse phospho-specific stat4 (pY693, clone 38, 
all from BD Transduction Laboratories), anti-mouse stat5 
(rabbit polyclonal), anti-mouse phospho-specific stat5 (Tyr694, 
rabbit polyclonal),  anti-stat6 (rabbit polyclonal, all from Cell 
Signaling), anti-mouse phospho-specific stat6 (Y641, clone 
16E12, Millipore Corporation), anti-mouse NF-κBp65 (rabbit 
polyclonal, Cell Signaling), anti-mouse NF-κBp105/p50 (clone 
12A2F, Abcam), anti-mouse ERk (panERk, clone 16), anti-
mouse ERk1 (clone Mk12), anti-mouse pan-JNk/SAPk1 
(clone 37), anti-mouse arginase I (clone 19), anti-mouse iNOS 
(clone 2), anti-mouse iNOS/NOS type II (clone 6, all from BD 
Transduction Laboratories). After washing, the membranes 
were stained with 16 ng/ml HRP-conjugated goat anti-rabbit 
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IgG or anti-mouse IgG (both from Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) diluted in Can Get 
Signal™ Immunoreaction Enhancer Solution 2 (Toyobo Co., 
Ltd.) for 1 h. The blots were developed with ECL (Amersham 
Pharmacia Biotech, Buckinghamshire, Uk), and the images 
were captured by the Cool Saver Lumino capture system 
(Model AE-6955, ATTO, Tokyo, Japan) before analysis using 
CS Analyzer software (ATTO). The membrane was then 
stripped and reprocessed with 2 µg/ml anti-GAPDH (clone 
9.B.88, United States Biological, Swampscott, MA, USA), and 
16 ng/ml HRP-conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc.).
siRNA silencing. Cells were transfected with 0.4 nmol/ml 
siRNA using Lipofectamine 2000 (Invitrogen Life Technologies) 
according to the manufacturer's instructions. The following 
siRNA sequences, designed by the manufacturer (Invitrogen, 
Carlsbad, CA), were used: M-CSFR1, 5'-UAGCCUUGCGG 
AUAAUGAACCCUCG-3' and 5'-CGAGGGUUCAUUAU 
CCGCAAGGCUA-3'; control siRNA, 5'-UAGCCCGUUCA 
GGCUAAUCAAGUCG-3' and 5'-CGACUUGAUUAGCC 
UGAACGGGCUA-3'.
Mitomycin C treatment of splenocytes. Splenocytes were 
prepared from male 6- to 8-week-old BALB/c mice. The 
collected splenocytes were treated with hypotonic buffer 
(0.155 M NH4Cl, 0.1 mM EDTA, 10 mM kHCO3) for 1 min to 
lyse red blood cells. The cells were then treated with 100 µg/ml 
mitomycin C (MMC) in RPMI-1640 medium for 30 min at 
37˚C. After washing with PBS three times, the cells were used 
as allostimulator cells in mixed lymphocyte culture.
Analysis of antigen presentation by T-cell proliferation. Allo-
antigen stimulation and ovalbumin antigen-specific T-cell 
systems were utilized. For the alloantigen stimulation system, 
responder cells were prepared as the negative population of 
magnetic immunobeading (Miltenyi Biotec, Germany) with 
anti-CD11b, CD11c, and B220 immunobeads. Responder cells 
were labeled with CFSE (Invitrogen) according to manu-
facturer's instructions for flow cytometric analysis. One million 
responder cells, 1x106 allostimulator cells, and 1x103 antigen-
presenting cells (F4/80+ cells treated with either control or 
M-CSFR1 siRNA for 5 days) were co-cultured in one well of 
a 24-well plate containing 2 ml medium for 5 days and then 
collected for analyses. For the ovalbumin-specific T-cell 
system, ovalbumin (OVA) was utilized instead of allostimulator 
cells, and OT-2 mouse-derived splenocytes were prepared by 
the same method used for responder-cell preparation in the 
alloantigen system. OVA (1 mg/ml), 1x106 CFSE-labeled 
responder cells, and 1x103 antigen presenting cells (F4/80+ cells 
Figure 1. Characterization of tumor-infiltrating F4/80+ cells. Mice were euthanized 14 or 21 days after tumor implantation, and tumor-infiltrating F4/80+ cells 
were purified using an F4/80 positive immunobeading method (A-C). Dead cells were excluded by Via-Probe (B), and the CD11b and F4/80 2-D histogram is 
shown (C). Appearance of F4/80+ cells after 24 h cell culture with medium is shown. Almost all cells adhered to the dish and demonstrated a short spindle 
shape (D). Representative data from three independent experiments are shown. 
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treated with either control or M-CSFR1 siRNA for 5 days) were 
co-cultured in one well of a 24-well plate containing 2 ml 
medium for 5 days and then collected for analyses.
For flow cytometric analysis, the cells were preincubated 
with 10 µg/ml anti-CD16/32 (clone 2.4G2, BD Biosciences, 
Rockville, MD, USA) at 4˚C for 30 min prior to staining. 
Via-Probe (BD Biosciences) was used for dead cell exclusion 
according to the manufacture's instructions. The following 
antibodies were used at 10 µg/ml: APC-conjugated anti-CD3 
(clone 145C11), PE-conjugated anti-CD4 (RM4-5), and 
Figure 2. Characterization of freshly-isolated tumor-associated macrophages (F4/80+ cells) based on M1/M2 classification. Real-time PCR analysis of TAM 
for the expression of cytokines, chemokines, and their receptors based on M1/M2 classification is shown as the relative expression level to GAPDH (A). The 
same cells were investigated with multiple PCR analysis (B). Representative data from two independent experiments are shown.
Figure 3. Effect of GM-CSF treatment on macrophage differentiation based on the M1/M2 classification of tumor-associated macrophages using real-time 
PCR. TAM were cultured with GM-CSF for 3 days. Real-time PCR analysis for the expression of cytokines, chemokines, and their receptors is shown relative 
to the expression level of GAPDH. Representative data from three independent experiments are shown.
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PE-conjugated anti-CD8b (clone 53-5.8, BD Biosciences). The 
cells were incubated with the antibodies for 30 min at 4˚C and 
washed with PBS. The samples were analyzed by a FACS 
Calibur flow cytometer and CellQuest software (Becton-
Dickinson Japan, Tokyo). For cell proliferation assays, 
co-cultured cells were mixed well, distributed into a 96-well 
plate (180 µl cells/well), and 20 µl CellTiter 96 reagent 
(Promega Corp, Madison, WI, USA) was added to each well. 
The cells were cultured for 1 h at 37˚C, and the reaction was 
then measured by a microplate reader (Bio-Rad Laboratories) 
at 490 nm and analyzed using MPM-3 Microplate Manager 
software (Bio-Rad Laboratories).
Statistical analysis. The Student's-t test was used for statistical 
analysis. P<0.05 was considered as a significant difference.
Results
Tumor-associated macrophages bear characteristics of both 
M1- and M2-type macrophages. To characterize purified 
tumor-infiltrating F4/80+ cells, mice were euthanized 14 or 
21 days after tumor implantation, and tumor-infiltrating 
F4/80+ cells were isolated. Purified cells were almost entirely 
F4/80high and CD11bhigh, which indicated that the population 
was suitable for consideration as tumor-associated macro-
phages (TAM) (Fig. 1). Macrophages were classified using the 
M1/M2 scheme (23) based on their expression pattern of M1/
M2 factors using real-time PCR analysis. As shown in Fig. 2, 
TAM expressed not only M2-type markers such as CCL22, 
CCL17, IL-10, and CD206, but also M1-type markers, including 
IL-1β, TNFα, and CXCL10. The data indicated that the TAM 
utilized in this study simultaneously expressed both M1 and 
M2 factors.
Tumor-associated macrophages do not change character 
significantly when cultured with GM-CSF. Because macro-
phages have been reported to demonstrate plasticity, we 
investigated whether TAM can be redirected to dendritic cells 
using in vitro GM-CSF treatment because GM-CSF has been 
used previously to investigate DC differentiation by monocytes/ 
macrophages (19). TAM were cultured with or without GM- 
CSF for 3 days (Fig. 3). The expression levels of M1-type 
markers (including IL-1β, TNFα, and CXCL10) decreased, but 
the levels of M2-type markers (including CD36 and CD206) 
were unchanged. The expression levels of CCR1, CCR2, CCR5, 
and IL-13 decreased, IL-1β was unchanged, and IL-6 and 
Figure 4. Effect of GM-CSF treatment on macrophage differentiation based 
on the M1/M2 classification of tumor-associated macrophages using multiple 
PCR analysis. F4/80+ cells were cultured with or without GM-CSF for 3 days. 
Multiple PCR analysis for the expression of cytokines, chemokines, and their 
receptors was performed (A). Appearance of TAM after 3 days of in vitro 
culture with GM-CSF (B). Representative data from three independent 
experiments are shown.
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IL-12 were only detected after GM-CSF treatment (Fig. 4). 
When the expression of intracellular signal transduction 
proteins was compared between freshly isolated TAM and 
TAM cultured for 5 days with or without GM-CSF treatment 
(Fig. 5A), a few differed across groups (including STAT1, 
p-STAT5, STAT6, NF-κB), but others did not. In terms of 
morphology, GM-CSF treatment apparently decreased the 
adhesive ability of TAM; the cells were round and floated in the 
medium (Fig. 5B and C).
Blocking the tumor-associated macrophage M-CSF pathway 
in the presence of GM-CSF leads to altered intracellular signal 
transduction. Because the importance of M-CSF in macro-
phage activation has been demonstrated (24), the combined 
effect of M-CSF signal blockade and GM-CSF treatment on 
TAM was then investigated in vitro. No significant differences 
were observed in the expression pattern of M1/M2 factors 
analyzed using multiple PCR (Fig. 6). In terms of TAM intra-
cellular signal transduction (Fig. 7A), the expression levels of 
all molecules were unchanged in TAM treated with control 
siRNA and GM-CSF compared to TAM cultured with GM- 
CSF alone, as shown in Fig. 5A. In contrast, M-CSFR 
knockdown by siRNA for M-CSFR1 led to increased expression 
levels of STAT5, STAT6, and NF-κBp65 (Fig. 7A). The 
morphology of cells treated with control siRNA and GM-CSF 
was similar to that of cells treated with GM-CSF alone (Figs. 5C 
Figure 5. Tumor-associated macrophages (F4/80+ cells) were cultured for 5 days in RPMI medium with or without GM-CSF. Immunoblot analysis of 
intracellular signaling pathways (A). Appearance of TAM from MCA38 tumors after in vitro culture without GM-CSF (B) and with GM-CSF (C). Represen-
tative data from three independent experiments are shown.
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and 7B). However, M-CSFR knockdown by M-CSFR1 
siRNA led to a change in cell morphology to a dendritic shape 
(Fig. 7C).
Blockade of the M-CSF pathway in conjunction with GM-CSF 
treatment sustains the antigen-presentation capability of 
tumor-associated macrophages. Finally, the antigen-
presentation capability of TAM was examined. T cells were 
stimulated, but proliferation did not differ between control 
and M-CSFR1 siRNA conditions (both with GM-CSF 
treatment), as analyzed by two different antigen-responder 
combinations (alloantigen and ovalbumin systems) (Fig. 8).
Discussion
Macrophages have been classified into two subtypes based on 
the concept of Th1/2 T-cell subtype classification, because 
macrophage differentiation is strongly influenced by IFNγ 
and IL-4, which are secreted by Th1- and Th2-type T-cells, 
respectively (25). Based on this classification, TAM have been 
reported to fall into the M2 subtype (23). In this study, TAM 
(tumor-infiltrating F4/80+ cells) were first assessed for their 
expression of cytokines, chemokines, membrane proteins, and 
intracytoplasmic signaling molecules related to macrophage 
activation and maturation. M1-type (IL-1β, TNFα, CXCL-10) 
and M2-type macrophage markers (CD206, CD36, CCL17) 
were found to be simultaneously expressed by TAM, indicating 
that our tumor-infiltrating F4/80+ cells had the unique charac-
teristic of expressing both M1 and M2 molecules (Figs. 1 and 2). 
These results are almost identical to previously reported 
findings that utilized tumor-infiltrating macrophages prepared 
by CD11b-positive immunobeading (22,26).
We previously reported that TAM strongly secrete TNFα, 
IL-1β, and TGFβ, and that inhibition of TGFβ blocked the 
immunosuppressive characteristics of TAM (22). We also 
reported that an immunogene therapy model utilizing IL-2 
and sTNFR2 in combination suppressed TAM differentiation 
(21). These data suggested that macrophages have plasticity, 
and that different tumor microenvironments can differentially 
activate and differentiate macrophages to unique tumor-based 
Figure 6. TAM M-CSFR knockdown by M-CSFR1 and control siRNA. Multiple PCR analysis of the expression pattern of M1/M2 factors. Representative data 
from three independent experiments are shown.
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phenotypes. This finding could be explained by the plasticity 
of macrophages for reprogramming as stated also previously 
(18,19,27). Therefore, in this study, we aimed to investigate the 
possibility that TAM could be redirected toward a dendritic 
cell-like phenotype by GM-CSF treatment in vitro, because 
GM-CSF was reported to be a strong monocyte differentiation 
factor for dendritic cells (28,29).
Contrary to our prediction, incubation of TAM with GM- 
CSF in vitro did not change the expression of M1/M2 molecules 
as determined and shown in Figs. 1 and 2 (Figs. 3, 4 and 5A), 
although the morphology of TAM changed to round cells that 
showed less adhesion to the culture dish (Fig. 5B and C). This 
could have been because TAM were more mature than mono-
cytes previously differentiated by GM-CSF alone in  vitro 
(28,30), suggesting that several factors were necessary for the 
redifferentiation of TAM. A single administration GM-CSF 
has also been shown not to be fully successful in tumor 
immunotherapy (31,32), which is supported by our present 
in vitro results concerning GM-CSF treatment alone. Therefore, 
in the case of GM-CSF tumor immunotherapy in vivo, TAM 
may remain at the tumor site and retain their immunosuppressive 
properties. Subsequently, we attempted to suppress M-CSF 
signaling, because M-CSF is essential for monocyte differ-
entiation into macrophages (33,34). Indeed, several reports 
suggest that blocking M-CSF signaling by M-CSFR knock 
out, anti-M-CSF antibody, or anti-M-CSFR antibody can 
change the function or morphology of macrophages and 
induce dendritic cell-like characteristics (35-38). Therefore, in 
this study, M-CSFR siRNA was used in the presence of 
GM-CSF, with the expectation that M-CSF signal blockade 
could suppress TAM maturation, while GM-CSF could redirect 
immature TAM toward a dendritic cell-like phenotype.
Interestingly, combination treatment of TAM with GM-CSF 
and M-CSFR siRNA affected the signal transduction pathway 
of TAM but not the expression pattern of M1/M2 marker 
molecules (Fig. 7). A number of previous studies have investi-
Figure 7. TAM M-CSFR knockdown by M-CSFR1 and control siRNA. Immunoblotting analysis of intracellular signal transduction (A). Appearance of TAM 
cultured with GM-CSF in RPMI medium (B). Appearance of TAM treated with siRNA (M-CSFR) in the presence of GM-CSF (C). Representative data from 
three independent experiments are shown.
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gated the STAT pathway in monocytes and dendritic cells. 
STAT5 was not induced in mature dendritic cells by GM-CSF 
treatment alone (39), although the same treatment of mono-
cytes induced STAT5 and monocyte differentiation into dendritic 
cells (40). STAT6 was expressed by immature dendritic cells 
and was induced by treating monocytes with IL-4, which 
resulted in dendritic cell maturation (40). In contrast, GM-CSF 
treatment of macrophages did not induce STAT6 expression, 
but IL-4 treatment of the same cells did induce STAT6 (41). 
The IL-6/STAT3 pathway was essential for the redirection of 
monocytes from dendritic cell differentiation toward macro-
phage differentiation, and STAT3 was essential for macrophage 
survival (42). In terms of TAM, STAT3 did not induce, but 
spleen monocytes of tumor-bearing animals expressed STAT3 
(43). STAT1 was consistently expressed at all steps of dendritic 
cell differentiation and was essential for the maturation of 
monocytes into dendritic cells (40). While STAT1 was expressed 
by TAM, monocytes from the spleens of tumor-bearing animals 
did not express STAT1 (43).
Previous findings and our present results indicate that 
treatment of tumor-infiltrating F4/80+ macrophages with 
M-CSFR siRNA in combination with GM-CSF induced 
Figure 8. Analysis of the antigen presenting capability of TAM. Antigen responder T cells derived from BALB/c and OT-2 mouse splenocytes were labeled 
with CFSE. CD4+ T cells among responder cells were analyzed by flow cytometry after stimulation with alloantigen (A) or ovalbumin antigen-specific systems 
(B). Representative data from two independent experiments are shown.
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STAT1, 5, and 6, all of which are essential for dendritic-cell 
maturation (40). Previous studies have shown that, in terms of 
the NF-κB pathway, p50 but not p65 are usually expressed by 
TAM (44-47). As shown in Fig. 7, GM-CSF and M-CSFR 
siRNA combination treatment significantly induced p65 
expression, while p50 and p105 expression levels were not 
affected by the treatment. These results indicated that the 
combination of GM-CSF and M-CSFR siRNA could induce a 
different cell signaling pathway from that originally utilized 
by TAM. GM-CSF and M-CSFR siRNA treatment did not 
affect the capacity for antigen presentation (Fig. 8). This finding 
is understandable given that activated macrophages already 
have the ability for antigen presentation (48,49).
Taken together, our present data indicate that our treatment 
model could not redirect TAM to a MoDC-like phenotype 
based on the analysis of M1/M2 marker expression (Fig. 6), 
but could direct cell signaling pathways toward a dendritic 
cell-like pattern. Thus, treatment of tumor-bearing hosts by 
factors, such as GM-CSF, and blockade of M-CSF, as utilized 
in this study, could affect TAM differentiation via the plasticity 
of macrophages. Indeed, blockade of the NF-κB pathway has 
been shown to redirect TAM from an immunosuppressive 
phenotype to one with tumor-killing activity (M1 type) (27).
Tumor immunotherapy is a useful therapeutic strategy 
because it has fewer adverse effects than chemotherapy (50). 
However, because immune mechanisms are complicated, the 
effects of immunotherapeutic drugs have not been fully 
understood. Controlling the maturation and differentiation of 
tumor-infiltrating immune cells is critical for the development 
of effective immunotherapies. Macrophages remain at the sites 
of inflammation (such as vascular wall and soft tissue), while 
neutrophils die after degranulation (51). Considering that TAM 
are immunosuppressive (10,52) and remain at the tumor site 
due to their macrophage characteristics, suppressing the function 
and maturation of TAM, in addition to considering how to elicit 
anti-tumor immune responses, is very important.
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